Publications
36
Citations
1,290
Est. group size
—
Recurring co-author estimate
Active years
14
Publishing since 2012
Kerry Hege conducts clinical research in pediatric hematology, focusing on blood clotting and bleeding disorders in children. Their work includes clinical trials testing treatments for conditions such as immune thrombocytopenia (a disorder where the body destroys its own platelets, causing bleeding risk) and venous thromboembolism (blood clots in veins), as well as studies on the diagnosis and long-term outcomes of these conditions in young patients.
Publication activity has been steady with year-to-year fluctuation, averaging about 2.8 papers per year over the last five years with notable peaks in 2019 and 2024.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
JAMA · 2025
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Blood · 2025
- What is in a name: defining pediatric refractory ITP
Blood Advances · 2024
- The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism
Research and Practice in Thrombosis and Haemostasis · 2024
- Clinical characteristics, treatment, and outcomes of provoked acute cerebral sinovenous thrombosis in patients <21 years old: findings from the Kids-DOTT Multinational Trial
Research and Practice in Thrombosis and Haemostasis · 2024
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
Blood · 2024
- The Fuvid Study: Functional Characterization of Children with Pulmonary Embolism in a Prospective Multicenter Cohort Study
Blood · 2024
- Clinical Characteristics, Treatment, and Outcomes of Provoked Acute Cerebral Sinovenous Thrombosis in Patients &lt;21 Years Old: Findings from the Kids-DOTT Multinational Trial
Blood · 2023
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
Blood · 2023
- Right on Schedule: Improving the Rate of Clinic Appointments Scheduled Prior to Hospital Hospital Discharge
Pediatric Quality and Safety · 2022
- Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism
JAMA · 2022
- Current practices in pediatric hospital‐acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium
Research and Practice in Thrombosis and Haemostasis · 2022
- Prophylactic Enoxaparin Against Catheter-Associated Thrombosis in Postoperative Cardiac Children: An Interrupted Time Series Analysis
Pediatric Critical Care Medicine · 2022
- How old is too old? <i>In vivo</i> engraftment of human peripheral blood stem cells cryopreserved for up to 18 years - implications for clinical transplantation and stability programs
World Journal of Stem Cells · 2020
- Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)
Blood Advances · 2020
- Blood×10
- American Journal of Hematology×3
- Research and Practice in Thrombosis and Haemostasis×3
- Blood Advances×2
- JAMA×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile